HIV self-testing for partners of postpartum women to facilitate HIV pre-exposure prophylaxis and antiretroviral therapy uptake: a protocol to adapt and pilot an intervention via a pilot randomised controlled trial in South Africa Authors: Christina Psaros, Ivana Beesham, Nzwakie Mosery, Zoya-Maria R Aoun, Anvita Bhardwaj, Lungelo Ndlovu, Nkazimulo Ntanzi, Madeline C Pratt, Jeremiah Chikovore, Jennifer A Smit, Lynn T Matthews Published: 2026 ABSTRACT AbstractIntroductionSouth African women are vulnerable to HIV acquisition during the postpartum period which can result in perinatal transmission via breastfeeding; many male partners do not know their HIV status. Biomedical approaches to preventing HIV for postpartum women include pre-exposure prophylaxis (PrEP) and antiretroviral treatment for male partners with HIV. Gaps in implementation include low uptake of PrEP among postpartum women and infrequent testing of men who may be motivated to test for HIV to protect the health of their infant.Methods and analysisWe will conduct a randomised pilot trial in KwaZulu-Natal (KZN) Province, South Africa among postpartum women and their male partners. The study will pilot a combination intervention consisting of cognitive behavioural strategies (including communication skills training, motivational interviewing and problem-solving) to promote HIV self-testing (HIVST) for Partners and PrEP uptake for HIV-uninfected Postpartum Women, the ‘H4P’ intervention. The study aims to determine the feasibility, acceptability and preliminary effectiveness of the H4P intervention. We will enrol 60 HIV-uninfected women, aged 18 years and older, in their third trimester of pregnancy and reporting a partner whose HIV-serostatus is unknown. Sixty male partners will also be eligible to enrol. Enrolled women will receive three oral HIVST kits to distribute to their male partners and standard of care information on HIVST and PrEP. Women randomised to the intervention arm will receive additional counselling and reproductive health-centred HIVST information for the male partner, including information about why HIV testing is important during their partners’ postpartum period. To evaluate feasibility, we will calculate screening-to-enrolment ratios for women and men, the number of women who distribute HIVST kits to their male partners and the number of men who test. Acceptability will be evaluated using the Client Satisfaction Questionnaire and qualitative interviews. Effectiveness will be assessed at 3 months by measuring the proportion of women initiating PrEP via self-report and urine tenofovir measurements or receipt of injectable PrEP and the proportion of men who test positive who link to HIV care. Qualitative interviews will explore perceptions of the intervention.Ethics and disseminationEthics approval for this study was obtained from the Human Research Ethics Committee at The University of the Witwatersrand, Johannesburg, South Africa (Reference number: 250612) and the Institutional Review Boards at Massachusetts General Brigham (2025P002271, Boston, Massachusetts, USA) and the University of Alabama at Birmingham (300015167, Birmingham, Alabama, USA) in the USA. Site support and approvals were obtained from the health facility and the KwaZulu-Natal Provincial Department of Health. Results will be disseminated through peer-reviewed manuscripts, reports and both local and international presentations.Trial registration numberNCT07194902.Keywords: HIV & AIDS, Randomized Controlled Trial, Feasibility Studies, Preventive Health Services, PUBLIC HEALTH STRENGTHS AND LIMITATIONS OF THIS STUDY A strength of this study is that it proposes an intervention that supports HIV prevention and/or HIV care among both women and men in the context of having children, via pre-exposure prophylaxis (PrEP) uptake, HIV self-test kit distribution and healthy-families centred resources to support men to test for HIV. A strength of this study is that it proposes an intervention that supports HIV prevention and/or HIV care among both women and men in the context of having children, via pre-exposure prophylaxis (PrEP) uptake, HIV self-test kit distribution and healthy-families centred resources to support men to test for HIV. We will collect objective measurement of PrEP use at 3 months follow-up, reducing reporting bias. We will collect objective measurement of PrEP use at 3 months follow-up, reducing reporting bias. This study will likely be conducted as injectable PrEP is deployed in South Africa; the intervention will be flexible with respect to PrEP modality. This study will likely be conducted as injectable PrEP is deployed in South Africa; the intervention will be flexible with respect to PrEP modality. A limitation is that the pilot study—designed to inform future larger-scale trial—only spans 3 months, thus preventing us from measuring longer-term impacts around PrEP persistence or time to/ever viral suppression for men who may be living with HIV. A limitation is that the pilot study—designed to inform future larger-scale trial—only spans 3 months, thus preventing us from measuring longer-term impacts around PrEP persistence or time to/ever viral suppression for men who may be living with HIV. Introduction Background In HIV-endemic settings, women are particularly vulnerable to HIV acquisition during the postpartum period, which can increase perinatal HIV transmission via breastfeeding.1 In a sample of women from seven African countries, including South Africa, the likelihood of HIV acquisition per condomless sexual act was up to four-fold higher during the postpartum period.1 A complex combination of biology and behaviour exacerbates the risk of postpartum HIV acquisition. Biological factors associated with pregnancy, such as high levels of oestrogen and progesterone that can induce changes in the genital tract, may increase susceptibility to HIV.1,4 The risk of HIV transmission extends into the postpartum period where women may resume sexual activity. Importantly, post-delivery rates of breastfeeding-associated HIV transmission are high among women who seroconvert postnatally relative to those who are HIV-positive at delivery.5 In the province of KwaZulu-Natal (KZN), South Africa, the HIV prevalence among women aged 15 years and older is 27% and6 data from antenatal HIV surveillance survey indicate the HIV prevalence among pregnant women is even higher at 37%.7 In KZN, up to 97% of HIV negative women engage in breastfeeding8 and about one-third of infants with HIV were infected via mothers diagnosed at delivery or while breastfeeding.9 Lower HIV testing rates and suboptimal linkage to HIV care and antiretroviral therapy (ART) among men impacts their health as well as that of their female partners and infants. Men in sub-Saharan Africa are less likely than women to know their HIV serostatus (79% vs 87%) and in 2020, the largest group of undiagnosed people living with HIV in sub-Saharan Africa was men aged 35–49 years.10 Men are less likely to link to HIV care, adhere to ART and suppress HIV viral load.11,13 Barriers to HIV testing among men include stigma, masculinity norms and other gender-related issues including perceptions of health facilities as female spaces, gender and power dynamics and broader health system challenges.14,17 Gender and power dynamics in intimate partnerships may result in women feeling unable to discuss sex or HIV testing with their partners.18 Gender roles may also impact pre-exposure prophylaxis (PrEP) uptake in postpartum women.19 20 Data from the antenatal HIV surveillance survey in South Africa indicate that although a third of pregnant women were eligible only 6.5% reported PrEP use during pregnancy.7 Barriers to PrEP uptake and use among women include fearing negative reactions from partners19 which may lead them to conceal their use.21 Furthermore, men may feel threatened by women’s access to an HIV prevention tool that can be used autonomously as it shifts gender-based power dynamics and challenges the status quo.22 For pregnant and postpartum women and their partners, the shared goal of ensuring that infants do not acquire HIV may influence HIV prevention behaviour. Most reproductive health interventions appropriately focus on women; however, providing such interventions for both men and women is critical to ensuring the health of men living with HIV (MWH) and their families.23 24 A study that evaluated a safer conception intervention for MWH and desiring children (Sinikithemba Kwabesilisa) provided proof of concept that male-centred care that addresses reproductive goals and leverages men’s desire to have HIV-uninfected children is a promising strategy for engaging and retaining men in HIV care in South Africa, while also reducing HIV incidence and perinatal transmission among women of reproductive age.25 This study found that at month-3, 75% (12/16) of men had disclosed their HIV serostatus to a partner, and 81% (13/16) had initiated ART, and all the latter had achieved viral suppression. Promoting the responsibility to build healthy families is consistent with some masculinity norms and increases men’s HIV care engagement26 suggesting that men may be more willing to self-test when their partners are pregnant or breastfeeding. A study conducted in Kenya observed that couples with greater relationship-centred motivations are more likely to engage jointly in couples HIV testing and disclosure of HIV status.27 In KwaZulu Natal, South Africa, in-depth interviews among men found that addressing the reproductive goals of MWH may promote male engagement in HIV care including testing.28 HIV self-testing (HIVST) kit distribution can trigger conversations about HIV prevention plans (including PrEP) postpartum, as women transition to a period of less regular contact with the medical system and less frequent HIV testing compared with being in antenatal care. Knowledge of partner’s serostatus may also support effective PrEP use in serodifferent couples.29 In a cohort of pregnant and postpartum women in South Africa, limited knowledge of partner serostatus was strongly associated with lower PrEP retention; PrEP users that were unaware of their partner’s serostatus prior to their first antenatal visit had significantly lower odds of returning for PrEP follow-up 3 months later.30 Data on the feasibility of HIVST kit distribution to male partners of postpartum women in South Africa is sparse despite emerging evidence of utility. A study in Kenya found that providing HIVST kits to pregnant women increased HIVST uptake among male partners by almost three times, compared with standard of care (SOC).31 Another study in Kenya observed 91% of antenatal women and 86% of women in postpartum care distributed HIVST kits to their partners, and among partners who used the HIVST kits, couples testing occurred in more than 50%.32 A South African study in Cape Town reported 66% of postpartum women on PrEP who received HIVST kits for their partners reported partner HIV testing, compared with only 17% of women who received standard HIV testing partner referral slips.33 A study conducted in Gauteng and North West provinces in South Africa reported both high rates of HIVST kit distribution and partner HIV testing among antenatal clients where 82% of antenatal clients offered kits to their partners and 98% of male partners reportedly used the kit34; however, the study did not include postpartum women. Men receiving HIVST kits from pregnant women in Malawi reported that delivery of HIVST kits by the partner was acceptable and reduced disclosure-related stigma.17 The same study also found that men felt that HIVST increased their sense of independence and control of the testing environment.17 In Uganda, male partners of pregnant women found it acceptable to receive HIVST kits from their partners and no serious adverse events were observed following testing.35 This manuscript describes a combination intervention that aims to promote HIVST for Partners and PrEP uptake for HIV-uninfected Postpartum Women (‘H4P’) in KZN, South Africa. Phase 1 of this study was completed in October 2024 and included two focus group discussions (FGDs) with 10 women and 10 men in South Africa, who had a child in the past year, to refine the content of the H4P intervention.36 The FGDs explored the use of HIVST in alignment with the Integrated Behaviour Model (IBM) (eg, attitudes, social norms and agency in the context of HIV prevention, HIVST and PrEP during postpartum), as well as barriers to HIVST specific to men and female partners. Additional areas explored included safety and concerns related to HIVST distribution and use, preferences for design of materials for HIVST, preferences on who should deliver test kits, opinions on the use and content of videos for HIVST and feedback on the H4P structure and content. Results suggest both men and women appreciated the at-home privacy of HIVST, which avoided potential stigmas associated with facility-based testing. Yet participants were concerned about the likelihood of emotional distress from receiving a positive result without the support of a healthcare professional. Both groups indicated dynamics related to traditional gender roles as well as the possibility of gender-based violence could be a barrier to women offering HIVST kits to male partners. Men and women expressed the importance of including an education component to the intervention as well as training on how to communicate with partners. For this current manuscript, we describe Phase 2 of the study, a randomised pilot trial of the H4P intervention, a multi-step PrEP uptake and intervention for postpartum HIV-uninfected women who report a partner of unknown serostatus and their partners, in the province of KZN, South Africa, to evaluate the feasibility, acceptability and preliminary effectiveness. Study aims and outcomes The primary aims of this study are to (1) determine the feasibility and acceptability of the H4P intervention through a randomised pilot trial with postpartum HIV-uninfected women in KZN with a sexual partner of unknown serostatus and (2) evaluate the preliminary effectiveness of H4P intervention at 3 months by assessing the proportion of women initiating PrEP and the proportion of men that test positive who link to HIV care. We will use qualitative methods to explore in greater depth experiences and perceptions regarding challenges, successes, barriers, facilitators and preferences of the H4P intervention. Methods and analysis Study design This study is a randomised pilot trial planned to be conducted between March and September 2026 that will pilot the H4P intervention for 60 postpartum HIV-uninfected women and their male partners (n=60) with unknown HIV-serostatus. The H4P intervention includes evidence-based cognitive behavioural therapy strategies, such as communication skills training, motivational interviewing and problem-solving. These strategies were selected based on their (1) inclusion in successful HIV treatment and prevention interventions,37,40 (2) appropriateness, based on a summary of Jamil et al,41 a meta-analysis of 14 HIVST randomised control trials targeting the processes involved in HIVST distribution, use and PrEP uptake, (3) our theoretical and conceptual model which was adapted from Choko et al (figure 1)17 and (4) a decade of work with women with HIV or at risk for HIV during perinatal periods, their partners and MWH planning for partner pregnancy.2342,55 Model of overarching individual, community, dyadic and structural factors that impact uptake of HIVST. H4P, HIVST for Partners and PrEP uptake for HIV-uninfected Postpartum Women; HIVST, HIV self-testing; IPV, intimate partner violence; PrEP, pre-exposure prophylaxis. Women will receive HIVST kits for distribution to male partners and standardised health information on PrEP and HIV prevention. Women will be asked a series of questions about the perceived safety of HIVST kit distribution to partners. Women with safety concerns will be advised that they should not distribute the kits but will remain in the study. Women randomised to the H4P intervention arm will also receive additional counselling, and male partners will receive reproductive health-centred information about why HIV testing is important. Feasibility and acceptability will be assessed. To evaluate preliminary effectiveness, we will calculate, across intervention/control arms at 3 months post-intervention, the proportion of women initiating PrEP among those whose partners test positive, do not test or do not share a test result, and the proportion of men with a positive test who link to HIV care. Individual qualitative interviews with a subset of up to fifteen enrolled women and all male partners in the intervention arm will be conducted to explore opportunities to optimise the intervention. Sample size and power justification The study has been powered based on previous research estimating HIVST kit uptake and data on the acceptability of women in sub-Saharan Africa delivering kits to their male partners. Assuming 53% kit uptake among women in our sample based on Pintye et al,56 we will screen approximately 115 women to enrol 60 who agree to accept HIVST kits and deliver them to their partners. With 60 participants, we will have 80% power to reject the null hypothesis that the probability that a partner accepts an HIVST kit is 0.88 or greater, if the true probability is 0.75 or less, based on the normal approximation to the binomial test, at the 0.05 one-sided significance level. Previous research on the acceptability of HIVST kit delivery by women in antenatal care to male partners17 suggests that we will likely reach thematic saturation with 20–30 qualitative interviews (eg, 10–15 women and 10–15 men). Study population and eligibility The study eligibility criteria for men and women are presented in tables1 2 below. For women, these include not living with HIV, aged 18 years and older, having a sexual partner whose HIV-serostatus is unknown and being pregnant for 30 weeks or longer. Eligibility criteria for men include confirming being a partner of the enrolled women and aged 18 years and older. Table 1Inclusion and exclusion criteria for womenInclusion criteriaExclusion criteria Identify as cis-gender womenAge ≥18 years≥30 weeks pregnantNon-reactive third trimester HIV testReports at least one unknown-serostatus sexual partnerFluent in English or isiZuluHas access to a phone and willing to give researchers permission to contact them for repeated assessmentsAble to provide informed consent Significant psychiatric illness that could interfere with participation or the ability to provide informed consent as determined by the study team Inclusion and exclusion criteria for women Identify as cis-gender women Identify as cis-gender women Age ≥18 years Age ≥18 years ≥30 weeks pregnant ≥30 weeks pregnant Non-reactive third trimester HIV test Non-reactive third trimester HIV test Reports at least one unknown-serostatus sexual partner Reports at least one unknown-serostatus sexual partner Fluent in English or isiZulu Fluent in English or isiZulu Has access to a phone and willing to give researchers permission to contact them for repeated assessments Has access to a phone and willing to give researchers permission to contact them for repeated assessments Able to provide informed consent Able to provide informed consent Significant psychiatric illness that could interfere with participation or the ability to provide informed consent as determined by the study team Significant psychiatric illness that could interfere with participation or the ability to provide informed consent as determined by the study team Table 2Inclusion and exclusion criteria for menInclusion criteriaExclusion criteria Confirm their identity and status as the partners of the enrolled womenMaleAge ≥18 yearsFluent in English or isiZuluHas access to a phone and willing to give researchers permission to contact themAble to provide informed consent Significant psychiatric illness that could interfere with participation or the ability to provide informed consent as determined by the study team Inclusion and exclusion criteria for men Confirm their identity and status as the partners of the enrolled women Confirm their identity and status as the partners of the enrolled women Male Male Age ≥18 years Age ≥18 years Fluent in English or isiZulu Fluent in English or isiZulu Has access to a phone and willing to give researchers permission to contact them Has access to a phone and willing to give researchers permission to contact them Able to provide informed consent Able to provide informed consent Significant psychiatric illness that could interfere with participation or the ability to provide informed consent as determined by the study team Significant psychiatric illness that could interfere with participation or the ability to provide informed consent as determined by the study team Recruitment and enrolment Recruitment of women Up to 60 pregnant participants will be recruited between 30–40 weeks’ gestation from public health antenatal clinics in KZN, South Africa. Notably, 94% of women in South Africa access at least some antenatal care57 and recruiting at the end of pregnancy is a means to recruit women as they prepare to transition to the postpartum period. Potential participants waiting in the clinic queue will be approached about study participation by a trained research assistant. Those who express interest will be invited to speak with a study research assistant to learn more about study participation and be screened for eligibility. Recruitment of male partner participants Women will be asked to identify male partner(s) who they would like to prioritise for HIVST kit distribution. An invitation letter will be provided to women by the research team that may be used to recruit male partners. The invitation letter will contain a description of the study, study contact information, and an invitation to participate in the study by contacting the study team directly. Contact to the study team may be made via an introduction from the woman, a ‘missed call’ on a study cell phone, a WhatsApp message sent to a study account, or a phone call directly to a study team member’s phone. To confirm male partner identity and couple status, a couple verification screening instrument58 will be used. All male partners who meet the inclusion criteria and who complete verification questions to confirm their identity and status as the partners of the women will be eligible for participation. Informed consent All eligible women will complete written informed consent to participate in the study (see online supplemental material). The men will complete consent procedures telephonically and the study staff will request and receive verbal consent. The consent form will include an overview of all study procedures, information about potential risks and benefits of participation, and contact information for study team members. The consent form will also state that participation is voluntary, that participants can refuse to answer any questions across all assessments, that they can withdraw from the study at any time and that study participation will not affect any services or treatment they receive at the clinic. No information about the study will be withheld from participants. Participants willing to participate will sign the informed consent form and will receive a copy of their signed form. Staff who conduct participant recruitment, screening, enrolment, HIV testing, and/or assessments will have been trained in ethical human subjects research including confidentiality, as well as screening and interviewing. Study procedures Study activities and arms are summarised in figure 2 and described in further detail below. Study flow diagram. HIVST, HIV self-testing; IPV, intimate partner violence; PrEP, pre-exposure prophylaxis; SOC, standard of care; TFV, tenofovir; 3MFU, 3-month follow-up. Baseline visit Enrolled women will complete a sociodemographic assessment and a quantitative questionnaire at baseline. Women will then be randomised via REDCap database programming linked to participant study ID; randomisation will occur at the 1:1 level to either the intervention (H4P intervention) or control arm. The random allocation sequence will be created by the research assistant in the US. Access to randomisation will be restricted to the project manager and two interventionists at the recruitment site and the research assistant in the US and all Principal Investigators (PIs) will have access to the randomisation sequence. Counselling session (women) Women will receive 15 to 20 minutes of counselling at a separate visit. All women will be provided with information and a demonstration per the SOC for HIVST kit distribution59 and will engage in a brief exercise that involves evaluating the risk of offering HIVST kits to their male partners. After the session, women will be provided with up to three OraQuick Rapid HIV-1/2 Antibody Tests HIVST kits and invitation letters for male partner distribution. The OraQuick HIVST kits include step-by-step instructions on use and interpretation of results. Intervention condition (women) Women randomised to the H4P intervention will engage in an additional 30–45 minute HIVST and PrEP uptake counselling intervention. This counselling intervention will cover (1) SOC PrEP information as described above, (2) communication skills training for HIVST kit distribution, (3) motivational interviewing strategies (eg, PrEP/HIVST pros/cons), (4) problem-solving barriers to PrEP uptake or HIVST distribution and (5) linkage enablers (eg, care sites, transportation, asking questions of providers). Participants in the intervention arm will also receive up to three OraQuick Rapid HIV-1/2 Antibody Tests HIVST kits and invitation letters for male partner distribution. HIVST kit distribution and male partners Men will be provided with the HIVST kit by their female partners (including directions for use, consistent with SOC), along with a letter describing how to contact the study team. Men will be asked to contact the study team as soon as they receive the HIVST kit to complete the consent visit. Follow-up visits for men will be primarily via telephone, however in-person visits may occur. All men receiving HIVST kits will be asked to verify if they have used the HIVST kit and for confirmatory testing results if applicable either by returning a used kit to the study team or by transmitting a photo of their test result. All men receiving the invitation letter will be provided with information on how to remain HIV-negative in the event of a negative test result, consistent with HIV-post-test counselling SOC. Men who screen positive on HIVST will be advised to go for confirmatory testing to a clinic or other facility offering HIV testing. Men who are diagnosed with HIV on confirmatory testing will be encouraged to visit their preferred public clinic for HIV management and care. All men who received HIVST kits but do not use their HIVST kit or those with a positive test result who do not link to confirmatory testing and care will receive brief counselling at the end of their follow-up assessment, regardless of study arm. Understanding why men choose to use the tests or not are part of the research questions this study aims to address. Intervention arm (male partners) Men in the H4P intervention arm will receive SOC information on HIVST and PrEP and in addition, will also receive a Quick Response (QR) code with their HIVST kit. The QR code will link to a brief (~10–15 minute) video created by the study team and featuring a racially and gender concordant study staff member; the video will communicate and reinforce the written material on how to conduct the HIVST. Information will also be provided on HIV treatment resources, why linkage to HIV care is needed in the context of the relationship with his female partner and gender norms (eg, increased risk for HIV during the postpartum period, risk of transmission to infant during breastfeeding, his role in protecting the family’s health). The video will also demonstrate a brief motivational exercise whereby men are asked to consider the pros and cons of linking to HIV care vs not (with examples), as well as a step-by-step guide to generate a concrete plan for linkage to care based on ‘linkage enablers’ (eg, identifying a clinic, planning transportation). Control arm (men) Men in the control arm will receive SOC information on HIVST and PrEP. Follow-up visit (month-3 for women) At the follow-up visit, a quantitative questionnaire will be completed and urine tenofovir (TFV) testing via urine dipstick test which reflects use in the past few days, will be conducted among women on TFV-based PrEP. Participants who tested positive during the study and have not linked to HIV treatment will be provided a brief HIV care counselling and will be referred to appropriate clinics and resources to manage their care. The team will then also follow-up with the participants to check on confirmatory test and link to care status in case the participant tested positive. Follow-up visits are expected to last approximately 30–35 minutes. In-depth qualitative interviews will also be conducted among a subset of men and women participants after their follow-up assessment. We do not anticipate harm related to trial participation. Participants will not be compensated for any harms experienced during participation. Participant compensation Participants will be reimbursed ZAR 400 (South African Rands) for participating in each study visit in which they complete an assessment, counselling session or interview for their time, inconvenience and travel-related expenses. Retention Research assistants will track participant retention, which will be reviewed weekly by the project manager in South Africa. If any participant cannot be located by phone or does not attend a scheduled study visit, participant tracing methods will occur which include the names of up to five individuals (collected at baseline) who will know how to reach the participant if the study team cannot contact her (eg, in the case of a non-working cell phone). The interviewer will call the first three individuals provided by the participant during the assessment to make an introduction. If these individuals are contacted to locate participants, reference to HIVST will not be made; instead, the study team will identify themselves as working for a maternal health study (or for some other reason as specified by the participant) to protect the participants’ confidentiality. This will be explained in detail to the participant at the time of enrolment. Additionally, to facilitate retention, if necessary, we will meet with participants telephonically, at their homes or any confidential location that is comfortable for them for study assessment visits. Fidelity of intervention All sessions involving contact with the interventionist will be audio recorded to monitor fidelity. Monitoring of the intervention will take into consideration both interventionist adherence as well as competence. We will develop a rating checklist for interventionist adherence including whether the specific components of the treatment modules were delivered. At least 10% of the sessions will be reviewed for clinical supervision (randomly selected). The interventionist will receive twice monthly supervision. Documentation of sessions will include session length and participant engagement. Safety Women will be screened for intimate partner violence (IPV) and depression at baseline and follow-up. If women report IPV or clinically significant depression, study staff will contact the local site investigators, and the participant will be provided with a referral to appropriate services and will be advised not to distribute the kits but to stay in the study, as they might benefit from the intervention session. The study staff will provide the participants with a list of IPV and mental health resources. Criteria for discontinuation Men and women may end study participation at any time if they desire and will be informed that withdrawal from the study will not impact their ongoing care at the clinic. Data collection Quantitative data Women and male partners will complete quantitative assessments at baseline and follow-up (approximately month-3 for women) separately. Questionnaires will include questions across the following domains: (1) sociodemographics (eg, age, race, country of origin, education, employment status, occupation and living situation) at baseline; (2) HIV and pregnancy characteristics and feelings towards current pregnancy for women (Pregnancy Risk Assessment Monitoring System (PRAMS) only at baseline)60 and Referent Pregnancy Intention for men (PRAMS only at follow-up)60; (3) Depression (Edinburgh Postnatal Depression Scale for the women and Center for Epidemiology Studies Depression Scale for the men)61,63; (4) Substance use; (5) Health Benefits for the women (Perceived Risk of HIV Scale only at baseline for women,64 PrEP attitudes scale only at follow-up)65; (6) Relationship Characteristics and Communication (Partner Communication Scale,66 Dyadic Trust Scale67,69; Gender-Equitable Men Scale only for the men69,71; Sexual Relationship Power Scale)6970 72,74; (7) IPV (Abuse Assessment Screen only for the women)75; (8) HIV-related stigma (Personal Stigma and Attributed Stigma Scale76 only at baseline for women and follow-up for men, PrEP Use Stigma Scale only at follow-up for women and men77; (9) Structural barriers only at follow-up for the women; (10) HIVST kit, PrEP use and HIV testing history at follow-up. Acceptability will be assessed via the Client Satisfaction Questionnaire (CSQ-8),78 which will be administered at the follow-up assessment only for participants in the intervention arm. All measures will be translated into the local language (isiZulu) as needed. Most instruments selected for this study have established validity and reliability through validation in South African and Sub-Saharan African populations; all have been used in this context before. Male partners will complete a locator form as soon as they contact the study team. Additionally, men will be asked to provide evidence of both their HIVST kit use/results and, if applicable, their confirmatory test (eg, return of used HIVST kit, photo of HIVST result, a paper or photo of confirmatory test result, CD4/viral load result or copy of their ART regimen). Women who report taking PrEP during their 3-month follow-up visit will also be asked to take a urine TFV test. Qualitative interviews In-depth qualitative interviews among females and male partners will explore challenges, successes, barriers (including safety concerns), facilitators and preferences around HIVST kit distribution, HIVST verification, confirmatory testing and verification and linkage to care (eg, PrEP or ART). Purposive sampling will be used to collect data from several groups of participants based on kit distribution (distributed vs did not distribute to male partner) and PrEP use (started vs did not start using PrEP). All interviews will be digitally recorded, translated if needed and transcribed. Transcription will be completed immediately so that the investigators can provide timely feedback to trained interviewers on their performance. Transcripts will be reviewed in real-time by the study team, and if sufficient depth is not achieved, the team will review the interviews and make edits to the interview guide and/or provide additional support to the interviewers. Patient and public involvement Public involvement was supported during phase 1 of the study where two FGDs were held with 10 men and 10 women recruited from the community in KZN; feedback from the discussions was used to refine the content of the H4P intervention that will be tested in this trial.36 Participants, community members and other relevant stakeholders will be involved in the reporting and dissemination of study findings as appropriate. The study team plans to provide regular (approximately quarterly) updates on the data collection process and study findings to the Community Advisory Board (CAB) as well as an annual update to KZN’s Department of Health. Data analysis To evaluate feasibility, we will calculate (1) the number of participants (women and men) screened, eligible and enrolled (whether >70% of those screened enrol/agree to participate); (2) the number of women who distribute a kit to their male partner; the number of women who learn their male partner’s status; and the number of male partners who use the kit, complete HIVST verification, use the QR code, and complete confirmatory testing. We will also record data on reasons for declining enrolment, and we will document non-distribution or non-use of the kits, complete verification, and complete confirmatory testing. Acceptability will be evaluated during the follow-up assessment using the CSQ-878 and qualitative exit interview data. Scores on the CSQ-8 will be categorised into four levels of satisfaction: ‘poor’ (score 8–13), ‘fair’ (score 14–19), ‘good’ (score 20–25) and ‘excellent’ (score 26–32) and treated as a categorical variable. Preliminary effectiveness will be assessed as the proportion of women whose male partners test positive or do not test/share result who initiate and use PrEP at 3 months postpartum, via self-report and point of care test for TFV and/or evidence of receipt of injectable PrEP with the denominator being all women enrolled in the study. We will also report the proportion of men with a positive HIV test (eg, result from confirmatory testing) and describe follow-up HIV care, including linkage to and initiation of ART, as self-reported by the participants. In exploratory analyses, we will estimate men’s uptake of HIVST, and undertake verification of HIVST results, and confirmatory testing using three logistic regression models. We will examine patterns in missing data to see if missingness is related to measured patient characteristics, and adjustments will be made for missing data using multiple imputation as appropriate, and adjust for multiple comparisons using the method of Hothorn, Bretz and Westfall.79 We will conduct descriptive modelling and report 95% CIs along with proportions. We will also estimate PrEP uptake among women in a separate logistic regression model. When appropriate, we will also conduct χ2 tests or Fisher’s exact tests. We will restrict attention to covariates that are of interest either before the study begins, or else after the baseline data has been collected, but blinded to the outcome variables. To identify the most relevant predictors while avoiding overfitting given our small sample, we will use Least Absolute Shrinkage and Selection Operator (LASSO) penalised logistic regression, which applies a regularisation penalty that shrinks coefficients of irrelevant covariates toward zero.80 The optimal penalty parameter will be selected via cross-validation. All regression findings should be interpreted as exploratory given the feasibility nature of this study. For some of the covariates that are measured by men and women, we will group to make a dyadic variable that measures if couples are answering the question similarly or are in discordance. We will also explore patterns of dyadic concordance and discordance between the couple for key variables including use of the HIVST kit through logistic regression models. We will perform exploratory multivariate analyses among the outcomes, including graphical methods and the calculation and testing of correlations and partial correlations. Statistical analyses will be performed using R and SPSS. Qualitative exit interview data will be explored for categories and themes around intervention acceptability using content analysis, an iterative, multi-step process as described by Miles and Huberman81 and Strauss and Corbin.82 We will use Dedoose software83 to organise data and facilitate analyses. Two study team members will independently review the transcripts to generate an overarching thematic framework for data interpretation, in which major and minor themes are identified. Thematic frameworks will then be compared for consistency, and discrepancies will be discussed until there is agreement. Data will be re-examined, messages will be extracted and highlighted, and ongoing discussion between coders will allow for further theorising and making interconnections between research questions, coding categories and raw data.81 Data management Quantitative data will be collected by trained study staff and entered into REDCap data management system using tablets or laptops. All tablets will be encrypted to the highest standard. Qualitative data will be collected by trained study staff and de-identified transcripts will be coded using Dedoose software83 to facilitate analyses. Data files will be sent to the investigators from the site via secure file transfer. Monitoring We have convened an independent Data Safety and Monitoring Board (DSMB) comprising individuals from South Africa with expertise across the following domains: (1) HIVST research; (2) biostatistics; (3) couples research and (4) applied clinical research. The DSMB has met once and will continue to meet at least annually (and/or after each phase of the trial) to allow for additional, external review of study procedures and participant safety. We have developed a DSMB manual outlining responsibilities, meeting procedures, and report template. The investigators are responsible for compiling and submitting annual reports. The DSMB members have reported no conflicts of interest and have been approved by the National Institute of Mental Health. The charter for this study can be requested from the corresponding author. Ethics and dissemination Ethics approval for this study was obtained from The University of the Witwatersrand Human Research Ethics Committee (Medical) in South Africa (Reference: 250612) and the Massachusetts General Brigham IRB (Reference: 2025P002271, Boston, Massachusetts, USA) and the University of Alabama at Birmingham IRB (300015167, Birmingham, Alabama, USA) in the USA. The protocol is registered with ClinicalTrials.gov (NCT07194902). Study updates and findings will be shared with the management in the facilities in which the study is being conducted, the KZN Provincial Department of Health, CAB meetings convened at Wits Match Research Unit (WMRU) and at WMRU biannual dissemination days. The data will be also presented at national and international scientific meetings and published in peer-reviewed journals. Supplementary material Footnotes Funding: Research reported in this publication was supported by the National Institute of Mental Health of the National Institutes of Health under Award Number R34MH132446; MPIs: CP & LTM. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The National Institute of Health did not have any role in the design, conduct, analysis, and reporting of the trial, including any authority over these activities. Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (https://doi.org/10.1136/bmjopen-2026-121917). Provenance and peer review: Not commissioned; peer reviewed for ethical and funding approval prior to submission. Patient consent for publication: Not applicable. Data availability free text: The data that support the findings of this study will be available upon reasonable request (eg, methodologically sound proposal and signed data use agreement) to the corresponding author (CP), following publication. The trial protocol and statistical analysis plan will also be available by request from the corresponding author (CP), following publication. Patient and public involvement: Patients and/or the public were involved in the design, or conduct, or reporting or dissemination plans of this research. Refer to the Methods section for further details. Data availability statement Data are available upon reasonable request. References Supplementary Materials Data Availability Statement Data are available upon reasonable request.